Of the markers selected to establish the potential role of various pathological pathways in increased risk in haemodialysis patients, ox-LDL and ET-1 were not found to be different between patients with and without diabetes, but VEGF-A was significantly elevated in diabetes patients prior to haemodialysis. Here, VEGFA is linked to diabetes mellitus.